Generation Bio (GBIO) to Release Earnings on Thursday

Generation Bio (NASDAQ:GBIO) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($2.81) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 9, 2026 at 5:00 PM ET.

Generation Bio Stock Performance

Shares of GBIO opened at $5.34 on Thursday. The stock has a market capitalization of $35.99 million, a PE ratio of -0.57 and a beta of 2.05. The company’s fifty day moving average is $5.50 and its 200 day moving average is $5.68. Generation Bio has a fifty-two week low of $3.00 and a fifty-two week high of $8.20.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GBIO. Zacks Research upgraded shares of Generation Bio to a “hold” rating in a report on Monday, January 26th. Jefferies Financial Group cut Generation Bio from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $11.00 to $5.00 in a research note on Tuesday, December 16th. Wall Street Zen raised Generation Bio to a “sell” rating in a research note on Saturday, February 14th. Wedbush set a $5.50 target price on Generation Bio and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.88.

Hedge Funds Weigh In On Generation Bio

A number of hedge funds have recently added to or reduced their stakes in GBIO. AQR Capital Management LLC bought a new position in Generation Bio in the first quarter worth approximately $36,000. Marshall Wace LLP purchased a new position in shares of Generation Bio in the 2nd quarter valued at $37,000. Shay Capital LLC bought a new position in shares of Generation Bio in the 3rd quarter worth $64,000. ADAR1 Capital Management LLC purchased a new stake in shares of Generation Bio during the 3rd quarter worth $136,000. Finally, Torno Capital LLC bought a new stake in Generation Bio during the fourth quarter valued at about $142,000. 95.22% of the stock is currently owned by institutional investors.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.